Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.75 USD | +2.97% | +4.09% | -32.61% |
May. 03 | Inari Medical Insider Sold Shares Worth $1,619,047, According to a Recent SEC Filing | MT |
May. 01 | Inari Medical Shares Jump on Higher Q1 Revenue | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.11 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.61% | 2.54B | C | ||
+73.46% | 12.41B | B- | ||
-15.61% | 8.23B | C+ | ||
+3.88% | 6.46B | C- | ||
+14.69% | 5.5B | D+ | ||
-5.53% | 5.33B | B | ||
+42.58% | 5.1B | - | ||
+10.80% | 1.99B | - | ||
-0.74% | 1.99B | - | ||
+10.31% | 1.77B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NARI Stock
- Ratings Inari Medical, Inc.